Potent and selective PPARγ agonist (EC50 values are 35.6 and 1053 nM for PPARγ and PPARα cofactor recruitment respectively. Enhances insulin sensitivity in obese, but not lean, rats. Antidiabetic and orally bioavailable.
|Storage||Store at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solubility||Soluble to 100 mM in DMSO|
References are publications that support the biological activity of the product.
Fürnsinn et al (1999) Chronic and acute effects of thiazolidinediones BM13.1258 and BM15.2054 on rat skeletal muscle glucose metabolism. Br. J. Pharmacol. 128 1141 PMID: 10578125
Dietz et al (2012) Comparative molecular profiling of the PPARα/γ activator aleglitazar: PPAR selectivity, activity and interaction with cofactors. ChemMedChem 7 1101 PMID: 22489042
If you know of a relevant reference for Edaglitazone, please let us know.
View Related Products by Product Action
Keywords: Edaglitazone, Edaglitazone supplier, potent, selective, peroxisome, proliferator-activated, receptors, PPARgamma, PPARg, PPARγ, agonists, diabetes, antidiabetics, R483, BM131258, insulin, sensitizers, R, 483, BM, 131258, Receptors, 4784, Tocris Bioscience
Citations for Edaglitazone
Citations are publications that use Tocris products.
Currently there are no citations for Edaglitazone. Do you know of a great paper that uses Edaglitazone from Tocris? Please let us know.
Reviews for Edaglitazone
There are currently no reviews for this product. Be the first to review Edaglitazone and earn rewards!
Have you used Edaglitazone?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.